Monte Rosa raises $96M Series B for drug development platform technology
The Boston-based company plans to develop small-molecule therapeutics that go after historically "undruggable" targets using a process known as protein degradation.
The Boston-based company plans to develop small-molecule therapeutics that go after historically "undruggable" targets using a process known as protein degradation.
The company sources product candidates from academic and commercial research and then launches subsidiary companies to develop them.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The California-based drugmaker plans to use the money to advance its investigational drugs with MOAs based on immune system responses.
Nasal obstruction is a significant problem that effects more than three million Americans each year. Spirox is developing a minimally invasive device that would decrease the need for surgery.
The private equity firm's fourth fund has a hard cap of $500 million. It has a vast portfolio in the life sciences, including Cidara Therapeutics, T2 Biosystems and Seragon Pharmaceuticals.